The trajectory of Sildenafil presents a interesting case for stakeholders in the drug sector. While initially a tremendous success, generating huge profits, the patent end and the subsequent flood of cheaper versions have significantly changed earnings. This poses questions about the ongoing viability of related medication developments and sugge… Read More